FDA Brief

Warning letters Drugs

FDA warning letter to

Makra Kozmetika D.O.O.

High riskIssued Sep 26, 2024Posted Oct 1, 2024Center for Drug Evaluation and Research (CDER)

FDA warns Makra Kozmetika over OTC drug manufacturing violations, including missing batch and ingredient testing, after April 2024 inspection.

What happened

FDA inspected Makra Kozmetika's drug manufacturing facility in Kranj, Slovenia, from April 8 to 12, 2024. FDA found significant violations of current good manufacturing practice (CGMP), including no finished-product quality testing before release, no identity testing of incoming ingredients, and no validated manufacturing, water, cleaning, or quality-unit systems. FDA reviewed the firm's April 29, 2024 response, found it inadequate, and placed the firm on Import Alert 66-40 on September 25, 2024.

What FDA found

  1. The firm did not test each finished drug batch for identity, strength, and objectionable microorganisms before release.

    21 CFR 211.165(a) and 211.165(b)
  2. The firm did not test incoming active ingredients and other components for identity and did not establish the reliability of supplier test results.

    21 CFR 211.84(d)(1) and 211.84(d)(2)
  3. The firm's batch records lacked critical manufacturing parameters, and it released drugs without validating the manufacturing process.

    21 CFR 211.100(a)
  4. The firm did not validate or monitor its water system to ensure water met appropriate microbial limits.

    21 CFR 211.100(a)
  5. The firm did not validate cleaning of non-dedicated equipment or keep cleaning procedures and logs.

    21 CFR 211.100(a)
  6. The firm did not establish a quality unit or written quality-system procedures for change control, complaints, recalls, investigations, corrective actions, annual reviews, adverse-event reporting, and training.

    21 CFR 211.22(a) and 211.22(d)

What FDA wants

FDA asks the company to correct the violations promptly and respond in writing within 15 working days, including what it has done and how it will prevent recurrence. If corrective actions cannot be completed in that time, the company must state why and give a completion schedule.

Who should pay attention

  • U.S. distributors and retailers selling Makra OTC drug products
  • companies buying or importing Makra drug products
  • quality teams managing supplier qualification for OTC drugs

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk